Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing

ALAMEDA, Calif.--(BUSINESS WIRE)-- #CRISPR--Scribe Therapeutics reports preclinical data at ASGCT 2026 demonstrating enhanced potency and specificity of engineered CRISPR technologies.